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Abstract
Background: Renilla Luciferase reporter gene (rLuc) GL4.82 and GL4.13 promoter are key player in transfection, but
precise knowledge of its targets in colon cancer remains limited. The aim of this study was to characterize the best
transfection technique to produce a stable transfected colon DLD1 (colorectal adenocarcinoma cell line), therefore
imaging based approaches were employed.
Results: DLD1 cells were transfected with a Plasmid (SV40-RLuc) carrying Renilla luciferase under the control of the
SV-40 promoter, by using two different transfection techniques. Cells expressing the required DNA were isolated
after antibiotic (Puramycin) selection. Clones of DLD-1/SV40-RLuc were produced using two different techniques
(96 well plates and Petri dish) and their florescence intensity was recorded using IVIS machine (Calliper Life
Sciences, Hopkinton, USA). Both techniques were characterized with the help of serial dilution technique. Results
from this study substantiated that electroporation is the best. As expected, clones varied in their specific
luciferase activity along with the dilutions. With the increase in cell concentration increase in intensity of
florescence was recorded.
Conclusions: Based on the results we are confident that this transfected cell line DLD-1/SV40-RLuc
(colorectal adenocarcinoma cell line) is the best for further Orthotopic Xenotransplantation Studies and in-vivo
experiments as well. Investigation shows that DLD1/SV-rLuc cells have gained little bit resistance against both drugs
therefore further study is suggested to know the reasons.
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Background
Human body is a complex of billions of cells, which
grow, divide, and die in programmed fashion, and when
any of these designed fashion undergoes uncontrolled or
abnormal causes cancer. Cancer is a lethal disease; in
2007, 1554845 cancer related deaths were recorded in
UK [1]. Good News is that despite increase in incidence,
cancer mortality is decreasing [2] yet there is great need
of new drug discovery and development. Drug dis-
covery and development procedure involves; acquisi-
tion, preclinical screening, production and formulation,
toxicology, clinical trials, and general medical practice [3].
Screening drugs for their intracellular effects is a crucial
part of the drug discovery and development process. To
support any investigational new drug, there is an essential
need of carefully designed preclinical drug in vitro and
in vivo studies. Most of the researchers in drug develop-
ment agree that the demonstration of anti-tumor efficacy
in preclinical, typically animal based model of cancer is a
key determinant in both, and compounds for testing
should have shown target biomarker modulation in vitro
and in vivo [4].
From 1950s to 1970s syngeneic murine models were
used. Subcutaneous transplantation of human tumor xeno-
graft in nude mice was used in next decades and now with
the advancement of transgenic knock out models, interest
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in using genetically engineered mouse models (GEMMS)
has sparked [5]. While syngeneic murine tumor models re-
main valuable for studying immunotherapeutic or targeting
metastasis, the human tumor xenograft models established
by inoculation of human cancer cell lines into the mice,
which is immunodeficient, have been used for test of
cytotoxic anticancer agents and new antineoplastic treat-
ment modalities [6]. Since early 1990 new drug develop-
ments have moved from general cytotoxic agents to
molecular target directed therapeutic, eventually, there
was a need to identify tumor types and individual pa-
tient tumors that express the target and could benefit
from therapies in clinical trials, therefore in vivo models
used in preclinical development should be oriented,
disease-to-disease or target directed [7]. This is still less
clear and point of debate that which is the best model
to use with respect to predict for clinical trails? Cur-
rently, nine out of ten experimental drugs fail in clinical
studies because we cannot accurately predict how they
will behave in people based on laboratory and animal
studies. In Biomedical sciences use of animals as models
to help understand and predict responses in humans, in
toxicology and pharmacology in particular remains both
the major tool for biomedical advances and a source of
significant controversy [8].
During 19th century rise in use of animals rose up
critically, which induced pressure on British government
to amend Cruelty to Animal Act of 1876 in 1986 [9]. Re-
cent developments of new techniques have permitted re-
searchers to minimize the use of animals at a certain
level. It has been very important element in the current
success of biomedical research. Very first example of this
was in the development of polio vaccine [10]. Since then
human and animal cells culture techniques have im-
proved greatly. Anyhow alternatives are nothing but new
techniques that may lead to reduce the use of animal in
research e.g. paper chromatography, radioimmunoassay,
non-invasive imaging and use of Orthotopic models etc.
has been main factor behind rapid development of bio-
medical research [11].
Currently research directions are towards specific
cancer target, due to advanced development in cancer
biology scientists are also focusing towards translational
medicine and diagnosis. In use mouse tumor models
have been improved in reliability of imitating human
disease. Orthotopic implantation (Organ-specific) repro-
duces human tumor and metastasis, which has replaced
ectopic subcutaneous implantation in experiments [12].
In Orthotopic models strong fluorescent are labeled with
green fluorescent protein along with video detectors, al-
lows the monitoring of details of growth, angiogenesis, and
metastasis. External imaging is limited by light scattering
in deep tissues, especially inside the skin. Signal reduction
is markedly eradicated by opening a reversible skin-flap in
the light path, which increases the detection sensitivity at
much higher extent [13]. The problem of this technique
depth of tissue is thereby minimized and many tumors that
were previously hidden are now clearly observable [14]. In
recent years, a significant development has been made in
the choice of imaging cancer non-invasively in murine
tumor models. This includes new materials that are im-
aging probes, which selectively accumulate in tumors, or
that become activated by tumor-specific molecules in
animal experimentation [15]. Other tumor imaging’s
techniques that rely upon the detection of gene expres-
sion (reporter) in the body of the animals have been de-
veloped [16], which made a significant impact on both
the versatility and the specificity of tumor imaging of
animals.
Optical imaging is rapidly developing field of research
aimed at non-invasively interrogates animals for disease
progression, evaluating the effects of a drug, assessing
the pharmacokinetics behavior of a drug, or identify-
ing molecular biomarker of disease. Optical imaging
is mainly based on quantifying the qualitative changes
in the emission of light by bioluminescence and fluor-
escence, which requires incorporation of a vector re-
porter gene into the cells [17]. In fluorescence imaging,
fluorescently tagged agent is injected in mice which
carry cells or tissue expressing a florescent transgene,
imaged using different light tight highly sensitive CCD
camera [18]. Bioluminescence imaging is based upon
the sensitive detection of visible light that is produced
during enzyme mediated oxidation of a molecular sub-
strate when that enzyme is expressed in animals as mo-
lecular reporter [19].
There are several other optical techniques being devel-
oped, as FTIR Spectroscopy, Raman Spectroscopy and
Multiphoton Imaging but, very low cost and high
throughput capability of Bioluminescence imaging and
Fluorescence imaging make these important to the drug
discovery and development process [20,21]. Key to non-
invasive imaging is to incorporation of these reporter
genes (talked above) in to the cells “Transfection”.
Transfection is the introduction of foreign DNA into
eukaryotic or prokaryotic cells [22]. It is the delivery of
DNA, mRNA, proteins, and macromolecules into the
cells. Goal for the transfection is to study the regulation
of gene as well as protein expression and function [23].
Frederick Griffith, 1928 first transformed nonpathogenic
pneumococcus bacteria into virulent variety by mixing
nonpathogenic pneumococcus with heat-killed patho-
genic bacteria. Avery, et al., 1944 reported that the pure
DNA is originally the transforming factor [24]. There are
different methods of transfection commonly used such
as DEAE-dextran for the delivery of nucleic acids into
cells for transient transfection [25], calcium phosphate
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variety of cell types [26], lipofection is much reproducible
and efficient than other transfection modalities [27], micro-
injection for the introduction of functional proteins, genes,
inhibitors of enzyme activities and antibodies into living
cells [28], protoplast fusion is very efficient with high level
of transfection about 10% [29], electroporation is proven to
be efficient method for transfection of many cell types [30]
though it requires very precise and accurate setting for
duration and strength of the current for each type of the
cells used and ExGen 500 used both in-vitro and in- vivo,
and wide range of cell types can be transfected with this
reagent [31]. It has shown very higher transfection
efficiencies as compared to other cationic lipids and
polymers [32,33].
The objective of this study was to develop a stable
transfected cell line DLD-1 colon adenocarcinoma and
at the same time characterize two different techniques
of transfection on the basis of their efficacy. Characterize
these transfected cells on the basis of their growth and
chemo sensitivity to two standard drugs (Doxorubicin,
MB2) for further use in orthotopic xenotransplantation
studies.
Results
Characterization of the techniques
DLD1 cells were transfected with a SV40-RLuc carrying
Renilla luciferase under the control of the SV-40 pro-
moter, using two different techniques. Cells expressing
the required DNA vector (Figure 1) were isolated using
antibiotic selection method [3]. To characterize the best
technique among both techniques used for transfection
(ExGen500 and Electroporation) in this study, substrate
coelenterazine 50 μg/ml was added to each well and output
was recorded, using IVIS machine with in 10 second of the
substrate addition. Electroporation and ExGen500 tech-
nique, Electroporation was found the best [3] shows, as
ELec1’s output was recorded 5.77 × 105 p/sec/cm2/sr while
ExGen2’s output was recorded 3.46× 105 p/sec/cm2/sr.
While from ExGen1, 2, and 3 ExGen 2 was the best and
from ELec1 and 2, ELec1 was found the best. As expected,
clones varied in their specific luciferase activity (measured
by standard luminometer -data not shown-). Figure 2
represents light emission in live cells corresponding to
five different clones after the treatment of cells with the
substrate 50 μg/ml Coelenterazine.
Bioluminescence intensity is directly proportional
to cell concentration
Following selection of the best clones serial dilutions were
prepared to show correlation between cell number and
photon output. Bioluminescence intensity of FLuc serial di-
lutions was recorded using IVIS machine. It was found that
bioluminescence intensity of FLuc cells increases in a grad-
ual manner, with the increase in cell concentration. At the
concentration of 1 × 105 cells/well it shows an output of
1.52 × 104 (p/sec/cm2/sr). While a slight decrease has been
noticed in the intensity of light at 5 × 105cells/ml where it
shows 1.02 × 104 (p/sec/cm2/sr) (Figure 3). Results were
measured (mean ± s.d). All types of rLuc cells were serial
diluted and treated with substrate. Results showed that
bioluminescence intensity of the ELec1 increases in a
gradual manner with the increase in cell concentrations,
while ExGen1 and 2 did not show gradual increase in the
light emission. On the other hand ExGen3 showed very
higheroutput of 4.70 × 105 (p/sec/cm2/sr) (Figure 4) at the
concentration of 5 × 105 cells/ml while at 1 × 106 cells/ml, it
showed a decrease in the output 3.67 × 105 (p/sec/cm2/sr)
(Figure 4). Anyhow ExGen2 showed consistent increase
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in output with higher concentrations of cells, 2.86 ×
105 (p/sec/cm2/sr) at 1 × 106 cells/ml. ELec1 was found
producing highest intensity than any other one, showing
6.12 × 105 (p/sec/cm2/sr) at 1 × 106 cells/ml.
Characterization on the basis of cloning
96 well cloning
After the selection of best clones, we also evaluated the
cloning techniques between 96 well plate cloning and ring
cloning, single cell clones of ELec1 (Best transfected cells)
from 96 well plates were imaged directly. As expected,
clones varied in their specific luciferase activity. We selected
7 best clones (Figure 5) on the bases of their light emission
ranging from 1.384 × 105 to 2.612 × 105 (p/sec/cm2/sr). In
(Figure 5) it represents light emission in living cells corre-
sponding to 7 clones after the treatment of cells with
25 μg/ml Coelenterazine.
Ring cloning
In case of ring cloning we selected ELec1 and ExGen2 to
image. Results shown in (Figure 6) light intensity of
ELec1 ranging from 4 × 105 to 1.57 × 106 (p/sec/cm2/sr),
and of ExGen2 it ranges from 1 × 105 to 1.275 × 106
(p/sec/cm2/sr). Three best resulting clones from ring
cloning were selected for further process.
Figure 2 All transfected cells (ExGen1, 2,3 and Elec1, 2) added substrate 5 μl of coelenterazine (50 μg/ml), Output (p/sec/cm2/sr) was
recorded using IVIS machine with in 10 second of the substrate addition.
Figure 3 FLuc cells plated at range of concentration from 5 × 10 cells/well to from 1 × 106cells/well, treated with 30 mg/ml D-Luciferin
at 1:200 dilution and Imaged using IVIS machine. Shows highest intensity of light at the concentration of 1 × 105cells/well. Results were
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Growth curve results
To ensure that transfected cell shows no difference in
their proliferation activity after transfection, we determined
growth curve for Normal DLD1, FLuc, rLuc cells, results
shown in (Figure 7). Following subculture, the control cells
progressed through a characteristic growth cycle, nearing
the peak phase at Day4. Normal DLD1 cells along with the
other transfected cells, Fluc and rLuc, were cultivated at
the concentration of 5 × 104 cell/ml. Growth of all cells ap-
pears to be very similar with Fluc having the highest rate of
Figure 4 Three independent DLD1/SV-rLuc/ExGen and Two independent DLD1/SV-rLuc/ELec clones were seeded in 96-well plates at
different cell densities, ranging from 5 × 10 cells/well to 1 × 106 cells/well and treated with the Renilla luciferase substrate
Coelenterazine. 50 μg/ml, output (p/sec/cm2/sr) was recorded using IVIS machine with in 10 second of the substrate addition.
Figure 5 Seven independent DLD1/SV-rLuc/ELec clones were selected after seeding of 10 cells/ml in 96-well plates and treated with
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growth as compare to others. All the cells have shown
nearly same trend of growth.
MTT ASSAY
In vitro growth inhibition by MB2 (ICT in-house drug)
and Doxorubicin was tested against all the cell types
wild type DLD1 and transfected DLD1/SV-FLuc, DLD1/
SV-rLuc cells, to ensure that transfected cells have no
change in their response to drug as compared to normal
DLD-1 cells. Cells were tested after 96 hours of drug ex-
posure. Data was recorded by using Teacan reader set at
the 540 nm filter. Results (Figures 8 and 9) described
that DLD1/SV-rLuc transfected cells have gained little
bit resistant against both of the drugs as ic50 for normal
DLD-1 cells for MB2 is (30 nM +/− 10 nM), for DLD1/
SV-FLuc = (30 nM +/− 10 nM) and DLD1/SV-rLuc =
(100 nM +/− 30 nM) (Figure 4). Ic50 of DLD1 cells for
doxorubicin is = (100 nM +/− 30 nM) (Figure 6) and of
DLD1/SV-FLuc = (100 nM +/− 30 nM) and DLD1/SV-
rLuc = (300 nM +/− 100 nM) was observed. Anyhow all
cell types have shown more or less same behavior to the
drug exposure. With increase in drug concentration, all
cells have shown gradual decay in percentage viability.
Results were measured as (mean ± s.d).
Figure 6 Nine independent clones of DLD1/SV-rLuc/ExGen2 and of DLD1/SV-rLuc/ELec1 were transferred from patri dishes to the
24-well plates at and treated with coelenterazine 25 μg/ml after overnight incubation. Output (p/sec/cm2/sr) was immediately quantified
using IVIS machine.
Figure 7 Above showing growth curve of Normal DLD1, DLD1/SV-FLuc, rLuc cells over the period of seven days. Cells were maintained
in 10 ml RPMI supplemented with 1% L-glutamine, 1% Sodium Pyruvate, and 5% Fetal bovine syrup (FBS), incubated at 37°C 5% CO2. Counted
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Discussion
Imaging techniques are emerging as important research
tools in the scientific industry, very useful especially in
diagnostics which are the main problem of the time. Even
though our understanding of functional roles of these re-
porter genes in cancers is steadily increasing, knowledge
about Renilla Luciferase reporter gene GL4.82 and GL4.13
promoter used in colon adenocarcinoma is still largely
missing. Hence focused on the characterization of the best
transfection technique to get the stable cell line after
transfection, which could result in a fine biomarker in
targeting colon adenocarcinoma cells. Supporting previ-
ous findings that imaging techniques are largely used in
tumor studies, cell growth profile of DLD1, DLD1/SV-rLuc
Cells and DLD1/SV-FLuc cells were established. Cell
lines demonstrated that proliferation levels of DLD1,
DLD1/SV-rLuc Cells and DLD1/SV-FLuc cells were sig-
nificantly same relative to non-tumorigenic cell lines
[34,35]. Growth reduction of DLD-1 cells upon transient
miR-145 transfection, which implies that miR-145 pos-
sesses a tumor-suppressor function in vitro has already
been reported [36].
Here, immunocytochemistry has been used as a method
of identification of potential targets using two different
drugs. It has the advantage over strictly computational tar-
get prediction that it is not only based on the presence of a
Figure 8 MTT assay result; The effects of MB2 on DLD-1, DLD1/SV-rLuc, and DLD1/SV-FLuc cells exposed to serial dilution of MB2
ranging from .1 ηM to 1 μM for 96 hours showing gradual decrease in % viability with the increasing dose of MB2. Absorbance values
were blanked against DMSO and the absorbance of cells exposed to medium only (i.e. no drug added) was taken as 100% cell viability.
Figure 9 MTT assay result; The effects of Doxorubicin on DLD-1, DLD1/SV-rLuc, and DLD1/SV-FLuc cells exposed to serial dilution of
Doxorubicin ranging from 10 ηM to 100 μM for 96 hours showing gradual decrease in % viability with the increasing dose of
Doxorubicin. Absorbance values were blanked against DMSO and the absorbance of cells exposed to medium only (i.e. no Drug added) was
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seed site and sequence features of the potential target, but
takes into account whether the target is expressed in the
considered cell line and whether the target is regulated on
the transcript level [37-39]. Since this approach is solely
based on changes observed on transcript level, targets
exclusively regulated by translational repression will not
be identified. Many of the targets identification techniques
used here have previously been implicated in cancer
[40,41]. A number of florescence genes with florescence
function, many of which have also been associated with
colon cancer, were identified as potential biomarkers based
on the microarray analysis [42-44]. The cell membrane as-
sociated fraction of VANGL1 increases with differentiation
and was demonstrated to co-localize with E-cadherin in
human colon cells [45,46]. Previously reported miR-145
targets including OCT4, SOX2 and KLF4 involved in the
promotion of stem cell proliferation were not expressed in
DLD-1 cells [47,48].
Experimental validation of these biomarkers demon-
strated a significant success in in-vitro studies as well
as in in-vivo [49]. The regulation in luciferase assays
further validates that this is the result of direct interac-
tions [50]. The reason of the different effects of lumi-
nesce in the different assays is likely due to a lack of
direct comparability between these assays [51]. This dif-
ference could also be due to other binding factors in-
volved in regulation of the endogenous transcript, as
these binding sites are not present in the 3′UTR or
cDNA fragments used in the cloned luciferase reporter
constructs [52-54].
A number of studies have linked increased use of these
biomarkers in cancer studies with increased cell motility
and tumor invasion [55]. In conclusion, using a micro-
array based approach we have identified additional tar-
gets for the cancer-associated miRNA miR-145 in colon
cancer cells [56]. These transfection techniques could be
a milestone in identifying different targets in colon can-
cers as well as other cancer types [57-59]. As the prob-
lem for the early diagnose stays the same in this era we
need to have more studies following these lines of the
studies which could save time and get very early diag-
nose of the cancer at the same time.
On the same time we strongly suggest the further use
of the same cell lines been transfected in this studies
in Orthotopic Xenotransplantation Studies, as we best
stable cells were frozen down already. These studies
can elaborate the use of such biomarkers in In-Vivo
studies.
Conclusions
Renilla Luciferase reporter gene GL4.82 and GL4.13 pro-
moter Renilla luciferases (rLuc) GL4.82 have emerged as
important gene regulators and are recognized as key
players in transfection (rLuc) GL4.82 is reported to be
down regulated in several cancers, but knowledge of its
targets in colon cancer remains limited. To investigate
the role of (rLuc) GL4.82 in colon cancer, we have
employed imaging based approach to characterize the
best transfection technique to get a stable transfected
colon DLD1 cell line. Based on the best of its imaging re-
sults in-vitro we hereby urge the use of this cell line in
Orthotopic Xenotransplantation Studies and in-vivo ex-
periments. DLD1/SV-rLuc cells gained little bit resistance
against both drugs; more studies designed for this par-
ticular plasmid need to be carrying out to know the rea-




DLD1 (colon adenocarcinoma cells) obtained from
European Collection of Cell Cultures Salisbury UK
(ECACC™). DLD1/Sv-Fluc transfected cells obtained from
IN HOUSE CELL CULTURE COLLECTION of ICT. Ros-
well Park Memorial Institute 1640 (RPMI) medium
supplemented with, 1% L-glutamine, 1% Sodium Pyruvate,
10% fetal bovine serum (FBS), all purchased from Sigma
Aldrich, St. Louis, USA. Hanks Balanced Salt Solution
(HBSS), T/E .25% Trypsin EDTA Solution, Serum free
media (SFM), Doxorubicin Hydrochloride, MTT (Thiazolyl
Blue Tetrazolium Bromide, Approx 98% TLC), DMSO
(Dimethyl Sulfoxide, ≥ 99.9% ACS Spectrophotometric
grade) and Puramycin dihydrochloride solution 10 mg/ml
also obtained from Sigma Aldrich, St. Louis, USA. Gene
Pulser Xcell Machine, Renilla Luciferase reporter gene
GL4.82, and GL4.13 promoter obtained from Promega,
Madison, USA. Fermentas, Maryland, USA provided
150 mM NaCl, and ExGen 500. Coelenterazine (native
coelenterazine), a substrate for Renilla Luciferase from
Biotium Hayward, CA (the compound (1 mg/ml) was
dissolved in methanol). D-luciferin Firefly potassium
salt, a substrate for Fire Fly Luciferase from Xenogen
Alameda, CA (A 30-mg/ml stock in PBS was filtered
through 0.22 μm filters before use). IVIS 50 imaging ma-
chine from Calliper Life Sciences, Hopkinton, USA. MB2
(Vascular Disrupting Agent) was taken from in house pro-
duction of ICT.
Cell lines, culture conditions
DLD1 cells, DLD1/Sv-Flu previously cultured and DLD1/
SV40-rLuc transfected with Renilla luciferase (rLuc)
GL4.82 reporter gene under the control of Simian Virus 40
GL4.18 promoter, cells were maintained in complete RPMI
1640 medium and incubated in humidified incubator at
37°C and 5% CO2 level. Passage of all types of cells was al-
ways done by seeding in complete RPMI 1640, incubating
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HBSS and counting manually with the help of haemocyt-
ometer after trypsinization.
Transfection of the cells
Renilla Luciferase reporter gene GL4.82 (Figure 2) and
SV40 GL4.13 (Figure 1) promoter been used to make the
reporter gene by cloning SV40 region from GL4.13 into
the NheI & Hind III site of GL4.82 made SV40-RLuc as a
vector reporter to transfect the DLD1 cells [60].
Transfection methods




1× 107 cells/ml were used for Electroporation Transfection,
so resuspended the required concentration of the cells in
400 μl of serum free media (SFM) after trypsinization of
the cells. Transferred the cell suspension to the 2 mm vial.
0.88 μg/ml SV40-RLuc were added to each sample (needed
20 μg of Plasmid in 400 μl of cell suspension). Gene Pulser
Xcell Machine was used for electroporation. Two methods
of electroporation were used;
Exponential electroporation; the machine was set at
voltage 250volts, Capacitance 1000volts, and resistance ∞.
Sample 1 was electroporated and these cells were named
DLD1/SV- rLuc/ELec1.
Square Wave Method; the machine was set at voltage
250volts, Pulse Length 10 nm, and Number of Pulse 1.
Sample 2 was electroporated and these cells were named
DLD1/SV-rLuc/ELec2. Following the transfection, Cells
were transferred in to T25 flasks and incubated in hu-
midified incubator at 37°C 5% CO2.
ExGen500 Transfection
Initially, we recommend the use of 1ug of DNA and
3.3 ul (6 equivalents) of ExGen 500 per well of 6-well
plate. Cells were plated in 6 well plates at 5 × 104 cells/well
and incubated overnight at 37°C 5% CO2 level. 150 mM
NaCl solution was made up. The ExGen 500 and DNA
complex was made by adding 1 μg of SV40-RLuc in to
100 μl of 150 mM NaCl, vortaxing gently and spinning
down and then adding ExGen 500 at the concentrations
shown in (Table 1). Following this, the solution was mixed
immediately for 10 second then incubated for 10 minutes
at room temperature. Then 100 μl of each sample was
added to each well containing 3 ml complete RPMI 1640
respectively. Then plate was incubated at 37°C and 5%
CO2 level for 48 hours. Colonies were visible after 2 to
3 weeks. Colonies were picked using sterile cloning rings
and expanded to form sub lines.
Puramycin selection/cloning
To select the cells expressing the required DNA vector
(Figure 1), all types of cell were treated with 50 μg/ml of
Puramycin because SV40-RLuc is Puramycin resistant
that works as selection marker. Optimal concentration
for puramycin was tested earlier at different concentra-
tions with normal DLD1 cells data not included here.
So, purely transfected cells expressing the required DNA
vector (Figure 1), sustained within the puramycin were
harvested and plated in Petri dishes and 96 well plates at
10 cells/ml following the procedure described earlier.
Plates were incubated at 37°C 5% CO2 level for 2–3 days.
Single cell clones were selected in both, Petri dishes and
96 well plates for imaging. Single cell best observed
clones in 96 well plates were imaged directly. While best
clones from Petri dishes were passaged to the 24 well
plates using method descried earlier.
Serial dilutions
To check the ratio of bioluminescence and cell numbers
both DLD1/SV-FLuc and DLD1/SV-rLuc cells were seri-
ally diluted. Each type of cells were serially diluted at the
concentrations ranging from 1 × 104 cells/well to 1 × 106
cells/well and DLD1/SV-FLuc at the concentrations ran-
ging from 5 × 10 cells/well to 1 × 106cells/well was plated
in 96 well plates. Incubated overnight at 37°C 5% CO2
level for imaging.
Table 1 ExGen500’s Volume used for transfection
Sample Amount of
DNA
Volume Of ExGen500 μl
at equivalents
DLD1/SV-rLuc/ExGen1 1 μg 8.23 μl
DLD1/SV-rLuc/ExGen2 1 μg 9.87 μl
DLD1/SV-rLuc/ExGen3 1 μg 11.52 μl
Table 2 Drug concentrations of MB2 and Doxorubicin used in MTT assay
Blank Control MB2 drug concentration
Blank Control .1 nM .3 nM 1 nM 3 nM 10 nM 30 nM 100 nM 300 nM 1 μM
Blank Control Doxorubicin Drug Concentration
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Imaging and quantification of bioluminescence data
The in vivo Imaging System (IVIS), consists of a cooled
camera (CCD) mounted on a light- tight chamber (dark
box), a camera controller, a camera cooling system, and
a Windows based computer system, were used for data
acquisition and analysis. Each 96/24-well plate sample
was placed in the specimen chamber mounted with the
CCD camera cooled to −90°C, with a field of view set at
25 cm above the sample shelf. The photon emission, trans-
mitted from cell samples was measured in p/sec/cm2/sr.
The bioluminescence color images were viewed using the
living image software overlay (Xenogen). Bioluminescence
was measured for the plates set up for imaging using
substrate 50 μg/ml Coelenterazine for RLuc cells and
30 mg/ml stock solution of D-Luciferin at 1: 200 dilution
for FLuc cells. To check the effect of lower concentration
of Coelenterazine, 25 μg/ml of Coelenterazine was used
to image ring cloning and 96 well plate cloning. Images
were taken within the 10 sec of the Coelenterazine
addition to the cells, due to the quick nature of the reac-
tion. Coelenterazine was tested alone1st in blank 2nd in
only media.
Growth curve
Growth curves were determined to ensure that transfected
cells show no difference to normal cells in their prolifera-
tion activity. Normal DLD1 cells, DLD1/SV-rLuc Cells
and DLD1/SV-FLuc cells were seeded at 5 × 104cells/ml.
Fourteen flasks of each line were seeded. To count, cells
were washed with Hanks, trypsinized, centrifuged, and
resuspended in 5 ml of media and then counted manually
using Haemocytometer every day for 7 days. Two flask of
each type of cells were used every day to have precise aver-
age count of the cell.
MTT assay
The MTT assay was done to check that transfected and
normal cells had same Chemosensitivity (transfection
has not changed their nature to react with the chemicals).
In brief, normal DLD1, DLD1/SV-rLuc Cells and DLD1/
SV-FLuc cells were seeded at 1x105cells/ml into 96 well
plates. Column 1 containing culture medium 200 μl/well,
only to blank the Spectrophotometer. Some drugs affect
the optical density (OD) of the medium and require a sep-
arate blank. Colum 2 containing 200 μl/well only cell sus-
pension but no drug exposure serves as control wells to
calculate the control cell survival percentage rest of the
plate cultivated with 180 μl/well of cell suspension. The
cells then left to adhere for 24 h in incubator at 37°C 5%
CO2 level. Next day, serial dilutions of both drugs were
prepared (Table 2).
MB2 ranges from 1 μM to .1 ηM and Doxorubicin
ranging from 100 μM to 10 ηM, and added 20 μl of each
dilution to the plates respectively leaving Blank and
control with no drug. The plates were incubated at 37°C
with 5% CO2 level for 96 hours. MTT stock solution
5 mg/ml was prepared in distilled water. Stock solution
of MTT was then diluted in complete RPMI 1640 at 1/
10 ratio. All the media from the plates were removed
and MTT solution 200 μl/well was added in each well
leaving blank. The plates were incubated for 4 hours at
37°C with 5% CO2. MTT was removed from the plates
very carefully and 150 μl of DMSO was added. Fi-
nally the absorbance at 540 nm of the plates was
read with the Tecan plate reader. MTT assay were done in
triplicate. Absorbance values were blanked against DMSO
and the absorbance of cells exposed to medium only
i.e. no Drug added was taken as 100% cell viability i.e.
the control.
Freezing down the cells
The best clones resulting high intensity of biolumines-
cence were washed with hanks, trypsinized, centrifuged
and resuspended in 1 ml of complete RPMI 1640. Cells
suspension was transferred to the 1.5 ml vials with 1:10
of DMSO and stored in freezer at −80°C for future use.
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